Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oxford Investments Holdings Inc. (OXIHF)
Toronto, ON, CA
Oxford Investments Holdings Inc., along with its subsidiaries, specializes in providing direct-banking and payment card solutions. Central to its offerings is the 'FocusKard' product suite. This includes a stored-value card that functions as an online-access account, providing a modern alternative to traditional cash, gift certificates, and paper checks. The versatility of this stored-value card is evident in its diverse applications, spanning payroll distribution, gift cards, travel expenses, insurance disbursements, membership programs, student accounts, and various incentive or promotional initiatives. Initially operating as Oxford Software Developers Inc., the company officially rebranded to Oxford Investments Holdings Inc. in December 2003. Founded in 2000, the firm's primary operations are managed from its headquarters in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -97.22% | -97.50% | -99.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-80.7% Q3'22: -87.0% (vs Q1'20)
-
EPS growth Medical - Pharmaceuticals: +20.2%+33.3% ★ Q3'22: +300.0% (vs Q1'20)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+671.6% Q3'22: +7,585.9% (vs Q1'20)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-570.0% Q3'22: +6,889.8% (vs Q1'20)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q3'22: -130.3% (vs Q1'20)
-
Share dilution Medical - Pharmaceuticals: +0.0%+4.1% Q3'22: +4.0% (vs Q1'20)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.60× Q3'22: 0.35× (vs Q1'20)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Donaghy | Founder, Chief Executive Officer, President, Chief Financial Officer & Executive Director | 113.6K | male |
| Benny Lee | Vice President of Corporate Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OXIHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
